Plasma factor VII-activating protease is increased by oral contraceptives and induces factor VII activation in-vivo

Thrombosis Research

Volumn 128, Issue 5, 2011, Pages

  Sidelmann, Johannes J ^a,b   Skouby, Sven O ^a,c   Kluft, Cornelis ^d   Winkler, Ulrich ^e   Vitzthum, Frank ^f   Schwarz, Herbert ^f   Gram, Jørgen ^a,b   Jespersen, Jørgen ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ESBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^e Klinikum Wetzlar Braunfels   (Germany)

^f Siemens Healthcare Diagnostics Products GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 7; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; FACTOR 7 ACTIVATING PROTEASE; GESTAGEN; GESTODENE; LEVONORGESTREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; MULTICENTER STUDY; NORMAL HUMAN; OPEN STUDY; PLASMA FACTOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CONTRACEPTIVES, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; FACTOR VII; FACTOR VIIA; FEMALE; GENOTYPE; HUMANS; SERINE ENDOPEPTIDASES; YOUNG ADULT;

EID: 80055090388     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.06.013     Document Type: Article

References (29)

1. J. Roemisch, A. Feussner, S. Vermohlen, and H.A. Stohr A protease isolated from human plasma activating factor VII independent of tissue factor Blood Coagul Fibrinolysis 10 1999 471 479 (Pubitemid 30013712)
2. J. Roemisch, S. Vermohlen, A. Feussner, and H. Stohr The FVII activating protease cleaves single-chain plasminogen activators Haemostasis 29 1999 292 299 (Pubitemid 30207459)
3. J. Roemisch Factor VII activating protease (FSAP): a novel protease in hemostasis Biol Chem 383 2002 1119 1124
4. J.W. Bryant, and Z. Shariat-Madar Human plasma kallikrein-kinin system: physiological and biochemical parameters Cardiovasc Hematol Agents Med Chem 7 2009 234 250
5. M. Etscheid, N. Beer, E. Fink, R. Seitz, and D. Johannes The hyaluronan-binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykinin Biol Chem 383 2002 1633 1643 (Pubitemid 35282983)
6. M.S. Parahuleva, S.M. Kanse, B. Parviz, A. Barth, H. Tillmanns, and R.M. Bohle Factor Seven Activating Protease (FSAP) expression in human monocytes and accumulation in unstable coronary atherosclerotic plaques Atherosclerosis 196 2008 164 171
7. J. Roemisch, A. Feussner, C. Nerlich, H.A. Stoehr, and T. Weimer The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP) Blood Coagul Fibrinolysis 13 2002 433 441 (Pubitemid 35001860)
8. B. Hoppe, T. Dorner, H. Kiesewetter, and A. Salama Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism Thromb Haemost 95 2006 907 908
9. J.J. Sidelmann, F. Vitzthum, E. Funding, A.M. Munster, J. Gram, and J. Jespersen Factor VII-activating protease in patients with acute deep venous thrombosis Thromb Res 122 2008 848 853
10. T. Gulesserian, G. Hron, G. Endler, S. Eichinger, O. Wagner, and P.A. Kyrle Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism Thromb Haemost 95 2006 65 67
11. N.M. Pecheniuk, D.J. Elias, X. Xu, and J.H. Griffin Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry Thromb Haemost 2008 453 455 (Pubitemid 351230981)
12. J.J. Sidelmann, S.O. Skouby, F. Vitzthum, H. Schwarz, and J. Jespersen Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women Climacteric 13 2010 340 346
13. A.L. Eilertsen, E. Hoibraaten, I. Os, T.O. Andersen, L. Sandvik, and P.M. Sandset The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis Maturitas 52 2005 111 118 (Pubitemid 41368033)
14. S.O. Skouby, J. Gram, L.F. Andersen, J. Sidelmann, K.R. Petersen, and J. Jespersen Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations Am J Obstet Gynecol 186 2002 969 977
15. O. Lidegaard, E. Lokkegaard, A.L. Svendsen, and C. Agger Hormonal contraception and risk of venous thromboembolism: national follow-up study BMJ 339 2009 b2890
16. J.P. Vandenbroucke, J. Rosing, K.W. Bloemenkamp, S. Middeldorp, F.M. Helmerhorst, and B.N. Bouma Oral contraceptives and the risk of venous thrombosis N Engl J Med 344 2001 1527 1535 (Pubitemid 32429213)
17. J. Jespersen, J. Endrikat, B. Dusterberg, W. Schmidt, C. Gerlinger, and J. Wessel A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel Contraception 72 2005 98 104 (Pubitemid 40966979)
18. The oral contraceptive and hemostasis study group The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study Contraception 67 2003 173 185
19. The oral contraceptive and hemostasis study group An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables. Outline of the protocol. Oral Contraceptive and Hemostasis Study Group Contraception 59 1999 345 355
20. J. Roemisch, A. Feussner, and H.A. Stohr Quantitation of the factor VII- and single-chain plasminogen activator-activating protease in plasmas of healthy subjects Blood Coagul Fibrinolysis 12 2001 375 383 (Pubitemid 32730497)
21. S. Stephan, H. Schwarz, A. Borchert, D. Bussfeld, E. Quak, and B. Simshaeuser-Knaub Tests for the measurement of factor VII-activating protease (FSAP) activity and antigen levels in citrated plasma, their correlation to PCR testing, and utility for the detection of the Marburg I-polymorphism of FSAP Clin Chem Lab Med 46 2008 1109 1116
22. E.M. Bladbjerg, J. Gram, J. Jespersen, and M.P. de Maat Internal quality control of PCR-based genotyping methods in research studies and patient diagnostics Thromb Haemost 87 2002 812 816 (Pubitemid 34516607)
23. U.H. Winkler Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel- containing oral contraceptives: a review Am J Obstet Gynecol 179 1998 S51 S61 (Pubitemid 28447223)
24. M.S. Parahuleva, H. Holschermann, A. Erdogan, E. Langanke, I. Prickartz, and B. Parviz Factor Seven Activating Protease (FSAP) levels during normal pregnancy and in women using oral contraceptives Thromb Res 126 2010 e36 e40
25. S.M. Kanse, M. Parahuleva, L. Muhl, B. Kemkes-Matthes, D. Sedding, and K.T. Preissner Factor VII-activating protease (FSAP): vascular functions and role in atherosclerosis Thromb Haemost 99 2008 286 289 (Pubitemid 351230957)
26. P. Quehenberger, U. Loner, S. Kapiotis, S. Handler, B. Schneider, and J. Huber Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives Thromb Haemost 76 1996 729 734 (Pubitemid 26388177)
27. U.H. Winkler Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism Contraception 62 2000 11S 20S
28. R. van Minkelen, M.C. de Visser, H.L. Vos, R.M. Bertina, and F.R. Rosendaal The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis Blood 105 2005 4898
29. N. Mackman The role of tissue factor and factor VIIa in hemostasis Anesth Analg 108 2009 1447 1452